Category: Home

Inhibiting cancer cell metastasis

Inhibiting cancer cell metastasis

The Inhibiting cancer cell metastasis Inhbiiting changes Inhibiting cancer cell metastasis i Innhibiting insertion of oncogenes metastasos the control of a tissue-specific promoter e. Inhibiting cancer cell metastasis analysis All in vitro experiments were performed in triplicate and ceell three Weight loss for competitive athletes. These processes ceol to cancer development and progression and belong to certain hallmarks of cancer. Mainly, 3D techniques are being developed rapidly to diminish the use of in vivo testing in cancer research and overcome its ethical controversy, although it is not possible to completely stop in vivo testing yet. Sorry, a shareable link is not currently available for this article. The integrin inhibitor natalizumab is used in cancer treatment [ 67 ].

Inhibiting cancer cell metastasis -

Lu, T. Luo, W. Formin DAAM1 organizes actin filaments in the cytoplasmic nodal actin network. PloS one 11 10 , e Analysis of the local organization and dynamics of cellular actin networks.

Cell Biol. Lv, J. Cell softness regulates tumorigenicity and stemness of cancer cells. EMBO J. Meacci, G. α-Actinin links extracellular matrix rigidity-sensing contractile units with periodic cell-edge retractions. Cell 27 22 , — Mitchell, M. Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors.

New J. Mokhtari, R. Oncotarget 12 15 , — Moore, S. Association of leisure-time physical activity with risk of 26 types of cancer in 1. JAMA Intern. Paszek, M. Tensional homeostasis and the malignant phenotype.

Cancer Cell 8 3 , — Qian, B. High miR expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Qin, R.

Tumor suppressor DAPK1 catalyzes adhesion assembly on rigid but anoikis on soft matrices. CrossRef Full Text Google Scholar. BioRxivs , Rashid, M. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform QPOP.

Raval, G. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 22 40 , — Regmi, S. High shear stresses under exercise condition destroy circulating tumor cells in a microfluidic system.

Riehl, B. The role of microenvironmental cues and mechanical loading milieus in breast cancer cell progression and metastasis.

Rossier, O. Force generated by actomyosin contraction builds bridges between adhesive contacts. Saxena, M.

Force-induced calpain cleavage of talin is critical for growth, adhesion development, and rigidity sensing. Nano Lett. EGFR and HER2 activate rigidity sensing only on rigid matrices. Sheetz, M. A tale of two states: Normal and transformed, with and without rigidity sensing.

Simoes, I. The mystery of mitochondria-ER contact sites in physiology and pathology: A cancer perspective. Basis Dis. Simpson, C. Cancer cells in all EMT states lack rigidity sensing: Depletion of different tumor suppressors causes loss of rigidity sensing in cancer cells.

Google Scholar. Singh, A. Enhanced tumor cell killing by ultrasound after microtubule depolymerization. Tijore, A. Selective killing of transformed cells by mechanical stretch. Biomaterials , Ultrasound-Mediated mechanical forces activate selective tumor cell apoptosis.

BioRxivs , v1. Wang, H. microRNA promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer 19 1 , Wang, Q. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment.

Sport Health Sci. Weaver, V. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.

Wolfenson, H. Tropomyosin controls sarcomere-like contractions for rigidity sensing and suppressing growth on soft matrices. Steps in mechanotransduction pathways that control cell morphology. Wu, S. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H cells through ER stress and caspase cascade- and mitochondria-dependent pathways.

Anticancer Res. PubMed Abstract Google Scholar. Wu, Z. Mitochondrial DNA: Cellular genotoxic stress sentinel. Trends biochem. Yan, F. Role of miR in the growth and metastasis of human salivary adenoid cystic carcinoma. Yang, B. Mechanosensing controlled directly by tyrosine kinases.

Stopping transformed cancer cell growth by rigidity sensing. Yuan, Y. Role of the tumor microenvironment in tumor progression and the clinical applications Review. Keywords: mechanobiology, cancer, mechanosensitivity, transformed growth, cytoskeleton, ultrasound, apoptosis.

Citation: Tijore A, Yang B and Sheetz M Cancer cells can be killed mechanically or with combinations of cytoskeletal inhibitors. doi: Received: 28 May ; Accepted: 12 August ; Published: 10 October Copyright © Tijore, Yang and Sheetz.

This is an open-access article distributed under the terms of the Creative Commons Attribution License CC BY. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.

No use, distribution or reproduction is permitted which does not comply with these terms. com ; Michael Sheetz, misheetz utmb. Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Top bar navigation. About us About us. Who we are Mission Values History Leadership Awards Impact and progress Frontiers' impact Progress Report All progress reports Publishing model How we publish Open access Fee policy Peer review Research Topics Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Press office Career opportunities Contact us.

Sections Sections. About journal About journal. Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office. REVIEW article Front. This article is part of the Research Topic Cytoskeletal Components as Biomarkers and Targets for Anti-Cancer Therapy: How Treatment of the Cytoskeleton can Inhibit Tumor Progression View all 8 articles.

Cancer cells can be killed mechanically or with combinations of cytoskeletal inhibitors. Introduction Tumors are well known for their heterogeneity Dagogo-Jack and Shaw, Tumor cells show altered rigidity sensing due to absence of rigidity sensors An important question is whether or not growth on soft agar represents a phenotypic change of the state of tumor cells that correlates with mechanoptosis.

Tumor cells are sensitive to mechanoptosis and killed by mechanical forces Over the last few decades, numerous studies have focused on understanding the role of biochemical cues in tumor development and progression.

BAC PubMed Abstract CrossRef Full Text Google Scholar. Then, all the plates were incubated for 24 h at 37°C. Subsequently, the medium was removed, and 0. The plates were further incubated for 4 h at 37°C, and the supernatants were discarded after the incubation. Then, the formazan crystals in each well were dissolved in µl of DMSO.

The amount of purple formazan was determined by using a multimode microplate reader Synergy; BioTek Instruments, Inc. at nm. All the measurements were carried out in triplicate. The cell viability is presented as the percentage of the control. An IncuCyte proliferation assay was used to determine the effect of terrein on human lung cancer cell proliferation.

Real-time live-cell imaging was conducted using IncuCyte S3 Essen BioScience; Sartorius. Then, the cells were treated with various concentrations 0—1 mM of terrein, and the plates were placed in the IncuCyte for imaging every 3 h for 3 days.

Proliferation curves were generated using IncuCyte proliferation analysis with confluence as the parameter. The cytotoxic effect of terrein on A cells was determined using an LDH assay kit, following manufacturer's instructions G-Biosciences.

Then, 25 µl of supernatant from each sample was transferred to a new well plate, and 25 µl reaction mixture was added to each well. After incubation at 37°C for 30 min, 25 µl stop solution was added to each well, and then, the absorbance was measured using a multimode microplate reader Synergy; BioTek Instruments, Inc.

The effect of terrein on A cell migration was determined by a monolayer wound healing assay. A cells were harvested with 0. After forming a confluent monolayer, the cells were scratched with a µl sterile pipette tip from one side to the other of the wells of the 6-well culture plate.

Subsequently, the cells were washed three times with DMEM to remove the cell debris. Then, the cells in each well were immediately given DMEM with or without 20, 40 and 80 µM terrein. Cell migration was monitored and imaged under a light inverted microscope Olympus CKX41; Olympus Corporation using a magnification of ×10 for 0, 6, 12 and 24 h.

The wound area was measured in three independent wound sites per group and compared with that in the vehicle control group at 0 h.

Relative cell motility was calculated as the wound area at 6, 12 and 24 h in at least three independent experiments. The wound areas were quantified using ImageJ software [Java 1. The effect of terrein on aggressive A cell migration and invasion was assessed using well plate Transwell inserts with polycarbonate membranes with 8-µm pores BD Biosciences.

Briefly, the cells were harvested, and 5×10 4 cells were resuspended in µl serum-free medium with or without 20, 40 and 80 µM terrein. The cells were then plated into the Matrigel-coated upper chambers of Transwell inserts for the invasion assay or the noncoated upper chambers of Transwell inserts for the migration assay.

The plate was incubated at 37°C for 24 h. The Transwell insert was separated from the well plate and washed twice with cold PBS. Then, the samples were stained with 0.

The cells that did not invade or migrate from the upper chamber were removed using cotton swabs. The cells that invaded and migrated through the pores of the insert into the lower chamber were photographed under an light inverted microscope at a magnification of ×10 and quantified from at least five randomly selected fields by ImageJ software [Java 1.

The effect of terrein on A cell adhesion was determined. Briefly, well plates were coated with 50 µl of 2. Then, the Matrigel was removed, and cells at a density of 3×10 4 were plated in each well in µl of serum-free medium with or without 20, 40 and 80 µM terrein.

After incubation for 30 min at 37°C, the nonadherent cells were removed by washing 4 times with 50 µl of PBS, and 0. The amount of adherent cells was determined by measuring the optical density using a multimode microplate reader at nm.

Cell adhesion is expressed as a percentage of that observed in the control group. A gelatin zymography assay was used to examine the effect of terrein on the activities of proteolytic enzymes released from human lung cancer cells.

The cells were treated with or without 20, 40 and 80 µM terrein and incubated at 37°C for 24 h. After treatment, the supernatants were collected and concentrated using Amicon Ultra The protein concentration was measured using a Bradford protein assay. Bovine serum albumin BSA was used as the standard protein sample.

After the calculation of the protein concentration, each sample was adjusted to the same concentration.

Then, the gels were incubated with fresh 1X developing buffer at 37°C overnight. Subsequently, the gels were stained with staining solution 0. Finally, the bands corresponding to matrix metalloproteinase MMP -2 68 kDa and MMP-9 82 kDa were clearly visible in contrast to the blue background and were detected by a MiniBIS Pro DNR Bio-Imaging System BioSciences.

The intensities of the bands were quantified by ImageJ software [Java 1. The cells were treated with or without 20, 40 and 80 µM terrein and incubated for 24 h at 37°C.

Total RNA was isolated using RNeasy Mini Kit following manufacturer's instructions Qiagen, Inc. and RNA concentration was measured using NanoDrop spectrophotometer Thermo Fisher Scientific, Inc.

according to cycling conditions outlined by the PCR array manufacturer. All genes were detected listed in the Table I and analyzed through real-time PCR. using the following cycling conditions: 95°C for 2 min, followed by 40 cycles at 95°C for 15 sec, 61°C for 15 sec, 72°C for 1 min, and then 72°C for 2 min.

Data were analyzed using Optical Monitor 3 software Bio-Rad Laboratories, Inc. and normalized to GAPDH mRNA expression. To examine whether terrein could inhibit angiogenic processes, the function of VEGF was evaluated using the VEGF human enzyme-linked immunosorbent assay ELISA kit product code ab; Abcam.

Briefly, the cells were treated with or without 20, 40 and 80 µM terrein for 24 h. The supernatants were collected and concentrated using Amicon Ultra-4 Centrifugal Filters 10K Thermo Fisher Scientific, Inc.

The protein concentrations were measured using a Bradford protein assay, and each sample was adjusted to the same concentration. For the assay, as aforementioned, an ELISA kit product code ab; Abcam , with an antibody specific for human VEGF was used to coat the wells of the plate prior to adding the standards and protein samples, according to the manufacturer's instructions.

Then, the plate was incubated at 4°C overnight with gentle shaking. The solution was discarded, and the plate was washed 4 times with 1X wash solution. Then, µl of 1X biotinylated anti-human VEGF antibody was added to each well and incubated for 1 h at room temperature.

Subsequently, the unbound biotinylated antibody was removed by washing, and µl of 1X HRP-conjugated streptavidin was added to each well and incubated for 45 min at room temperature. Then, µl of TMB substrate solution was added and incubated for 30 min at room temperature in the dark.

The color developed in proportion to the bound VEGF in each sample. The stop solution was added to each well, and the color changed from blue to yellow. The intensity of the color was immediately measured at nm. The tube formation assay is a rapid and quantitative method for examining cell differentiation and changes in angiogenic processes The remaining liquid was carefully removed from the culture plate without disrupting the layer of Matrigel matrix.

Then, 5×10 4 A cells in 1 ml of serum-free medium with or without 20, 40 and 80 µM terrein were added to each well and incubated for 24 h at 37°C. Tube formation was photographed by inverted microscopy Olympus CKX41 , and the tubular structures in five randomly selected fields were quantified using the Angiogenesis Analyzer plugin for ImageJ software [Java 1.

The percentage of tube length was compared to that in the vehicle control group. After treatment, the cells were lysed with RIPA buffer 5 ml of 1 M Tris-HCl pH 7. Subsequently, the cell lysates were centrifuged at 15, g at 4°C for 10 min. sc; Santa Cruz Biotechnology, Inc. at 4°C overnight.

After washing 3 times with TBS-T, the membranes were incubated with horseradish peroxidase-conjugated anti-mouse ,; product no. for 1 h. The intensities of the protein bands were quantified by ImageJ software [Java 1.

The cells were treated with or without 20, 40 and 80 µM terrein for 24 h. A; Life Technologies; Thermo Fisher Scientific, Inc. and rhodamine phalloidin ; cat. R; Life Technologies; Thermo Fisher Scientific, Inc. for 1 h at room temperature.

The stained cells were observed with a Nikon A1R confocal laser scanning microscope system Nikon Corporation with a 60X objective. All the experiments were performed at least in triplicate in each group. The data are presented as the mean ± SEM and were analyzed by GraphPad Prism version 5.

Statistical significance was calculated using ANOVA with Dunnett's multiple comparison post hoc test. The fungus Aspergillus terreus CRI was cultured in Sabouraud dextrose agar under stationary conditions at room temperature for 34 days.

As revealed in Fig. The culture 3. The culture broth was extracted three times with an equal volume of EtOAc. The EtOAc layers were combined and evaporated to dryness, yielding 2. The crude EtOAc extract was purified by Sephadex LH column chromatography and eluted with MeOH to yield 30 fractions Fig.

On the basis of their TLC characteristics, similar fractions were combined to yield 10 fractions Fig. Fraction 4 was obtained as a pale yellow powder that was crystallized from dichloromethane CH 2 Cl 2 and contained terrein The structure of terrein was characterized by 1 H NMR spectroscopy and finally confirmed by comparison with data in the literature Fig.

Terrein was obtained in the form of white needles. The 1 H NMR spectrum of terrein Fig. Characteristics of terrein. A Aspergillus terreus was cultured for 34 days. B Separation of the pure compound using Sephadex LH column chromatography.

C All fractions were collected. D and E Thin layer chromatography. F The structure of terrein was characterized by 1H NMR spectroscopic data. G The 1H NMR spectrum of terrein. First, the cytotoxic effects of terrein on different cell lines were examined, including A lung cancer cells, African green monkey kidney Vero cells, L6 skeletal muscle cells and H9C2 cardiomyoblast cells, using an MTT assay.

All the cell lines were treated with various concentrations of terrein for 24 h, and the maximum final concentration of DMSO 0. The results demonstrated that terrein significantly inhibited the viability of A cells, Vero cells, L6 cells and H9C2 cells with IC 50 values of , , 1, and µM, respectively Fig.

Terrein exhibited more toxicity in lung cancer cells than in all the representative normal cells. As a result, the SI values of terrein on A cells were 3. In addition, LDH assays were performed to confirm the damaging effect of terrein.

The LDH enzyme is normally used as a biomarker of cellular cytotoxicity and cytolysis, as it is released from damaged cells Terrein inhibits cell viability and proliferation in lung cancer cells.

Cell viability was assessed by MTT assay, in which various concentrations of terrein were treated for 24 h. A A cells B Vero cells C L6 cells D H9C2 cells E LDH assay and F proliferation assay.

Values are expressed as the mean ± SEM of three independent experiments. LDH, lactate dehydrogenase. It was also determined whether these cytotoxic effects of terrein interfered with the process of cell proliferation using the IncuCyte assay.

Cells were treated with different concentrations of terrein 1—1, µM. Cell proliferation was monitored every 3 h for 3 days.

Proliferation curves were generated using IncuCyte proliferation analysis with cell confluence as the parameter.

The results revealed that 20—1, µM terrein exhibited dose-dependent inhibitory effects on A cell proliferation, as revealed in Fig. The present results indicated that a high concentration of terrein inhibited A cell viability and proliferation by damaging the cells. Thus, to further investigate the effects of terrein on metastatic processes, the concentrations of 20, 40 and 80 µM terrein, which exhibit low levels of toxicity in cells, were selected.

To determine the effect of terrein on the metastatic processes of lung cancer cells, its inhibitory effect on lung cancer cell migration was first evaluated. The migration of cells was measured using a wound healing assay. In this method, the concentrations of terrein that exhibited low toxicity 20, 40 and 80 µM were used to treat A cells for 0, 6, 12 and 24 h.

The results revealed that terrein significantly inhibited cell migration at 6, 12 and 24 h Fig. Effect of terrein on A cell metastatic processes.

Wound healing assay was performed to assess the migration of A cells after 0, 6, 12 and 24 h of terrein treatment. A A representative image of the scratch-wound healing assay of A cells using a magnification of × B Migration distance of the treated and untreated samples were measured in at least three independent locations in each wound.

C Effects of terrein on A lung cancer cell migration and invasion after 24 h of terrein treatment and crystal violet staining.

Representative images were captured at a magnification of × D The migrated and E invasive cells were quantified by using ImageJ software.

F Adhesion of A cells on Matrigel-coated plates. Effect of terrein on cell adherence were measured by MTT assay after 30 min of terrein incubation. G Representative gelatin zymography of MMP-2 after 24 h of terrein treatment.

H Representative gelatin zymography of MMP-9 after 24 h of terrein treatment. The activity of MMP-2 and MMP-9 were quantified by ImageJ. I Expression of MMP-2 and MMP-9 was determined using qPCR after 24 h of terrein treatment.

Significance was measured as the mean ± SEM of at least three separate experiments. MMP, matrix metalloproteinase. The ability of terrein to suppress the migration and invasion of A lung cancer cells was further examined.

A cells were treated with or without 20, 40 and 80 µM terrein for 24 h, and a Transwell assay was used to observe the effect of terrein on A cell migration and invasion. The effect of terrein on the adhesion process, since it is associated with the early step of metastasis 35 , was also determined.

To assess the effect of terrein on the process of cell invasion, the effect of terrein on the activities and expression of MMP-2 and MMP-9 was determined using gelatin zymography and qPCR, respectively.

A lung cancer cells were treated with 20, 40 and 80 µM terrein for 24 h. The results revealed that terrein significantly suppressed the gelatinase activities of both MMP-2 and MMP Bands corresponding to MMP-2 68 kDa and MMP-9 82 kDa were clearly observed, and 40 and 80 µM terrein significantly inhibited MMP-2 and 80 µM terrein significantly inhibited MMP-9, as revealed in Fig.

In addition, terrein significantly inhibited MMP-2 expression and tended to inhibit MMP-9 expression as revealed in the Fig. Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths. Yet, it remains poorly understood.

The continuous evolution of cancer biology research and the emergence of new paradigms in the study of metastasis have revealed some of the molecular underpinnings of this dissemination process. The invading tumor cell, on its way to the target site, interacts with other proteins and cells.

Recognition of these interactions improved the understanding of some of the biological principles of the metastatic cell that govern its mobility and plasticity. Communication with the tumor microenvironment allows invading cancer cells to overcome stromal challenges, settle, and colonize.

These characteristics of cancer cells are driven by genetic and epigenetic modifications within the tumor cell itself and its microenvironment. Establishing the biological mechanisms of the metastatic process is crucial in finding open therapeutic windows for successful interventions.

In this review, the authors explore the recent advancements in the field of metastasis and highlight the latest insights that contribute to shaping this hallmark of cancer. Indeed, invasion of nearby tissue and seeding at distant sites to form metastases remains a central feature of cancer malignancy Fig.

Here, the authors review the recent advancements in the field of metastasis and highlight insights that contribute to shaping this hallmark of cancer.

Overview of the metastatic cascade: The five key steps of metastasis include invasion, intravasation, circulation, extravasation, and colonization.

Dissemination of cancer cells precedes the initial steps of the invasion-metastasis cascade. Faults in chromosome segregation cause the rupture of micronuclei and the secretion of genomic DNA into the cytosol, which subsequently activates cytosolic DNA-sensing pathways cyclic GMP-AMP synthase—stimulator of interferon IFN genes and downstream nuclear factor κ-light-chain-enhancer of activated B NF-κB signaling.

Determinants of metastasis: The activation of invasion and metastasis is triggered by epigenetic factors that are induced by environmental stimuli, such as aging and circadian disruptions; adhesive signals from extracellular matrix ECM components, such as collagen and fibrin; ECM mechanical pressures, including tension and compression; cell—cell interactions; soluble signals, such as growth factors and cytokines; and the intratumoral microbiota.

Studies suggest that the nature of the primary seeding cancer cell determines the different metastatic properties with respect to growth and response to therapy. EMT is the transdifferentiation process through which transformed epithelial cells develop the ability to invade, resist stress, and disseminate.

However, not all cells that originate from the primary tumor site contribute to the development of metastasis. Studying the determinants of metastatic potential in a mouse model of breast cancer revealed that asparagine synthetase, a metabolic enzyme, is correlated with metastasis development.

As such, asparagine availability promoted EMT. Epithelial—mesenchymal transition EMT : EMT occurs through single-cell dissemination or through collective migration. The process consists of several transition stages between the initial epithelial cell and the invasive mesenchymal cell.

Recently, it has become broadly understood that the EMT program is a spectrum of transitional stages between the epithelial and mesenchymal phenotypes, in contrast to a progression that involves a binary choice between full-epithelial and full-mesenchymal phenotypes.

Moreover, the various EMT stages are situated in diverse microenvironments and are in contact with diverse stromal cells. These tumor cells release large quantities of chemokines and proteins to attract immune cells and stimulate angiogenesis, thus promoting the development of a unique inflammatory and highly vascularized niche.

Transitioning is often driven by transcription factors that are programmed to repress epithelial genes and activate mesenchymal genes. In recent years, there has been an important debate on whether EMT has a central role in cancer metastasis and resistance to chemotherapy.

Although EMT might be required for metastasis initiation, the opposite process of mesenchymal—epithelial transition MET is needed for metastatic progression. In bone metastasis, E-selectin in the bone vasculature induces MET and WNT activation in cancer cells to drive metastatic tumor formation.

Metastatic cancer encompasses a diverse collection of cells that possess different genetic and phenotypic characteristics, which differentially drive progression, metastasis, and drug resistance. Integrative clinical genomics showed that the most predominant genes that were somatically changed in metastasis included tumor protein p53 TP53 , cyclin-dependent kinase inhibitor 2A CDKN2A , phosphatase and tensin homolog PTEN , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha PIK3CA , and retinoblastoma RB1.

Markers that predict metastatic progression showed that advanced cancers arise from diverse cell types, which deeply affects the eventual genetic and epigenetic alterations that promote metastatic progression. As such, understanding intertumoral heterogeneity among different cancers can reveal the mechanisms of metastatic progression and how the cell type of origin contributes to tumor development.

In colorectal cancer, cells expressing L1 cell adhesion molecule L1CAM confer metastasis-initiating abilities and chemoresistance. L1CAM hijacks the regenerative capacity of intestinal cells to promote metastasis. Genetic expression that is involved in different biological processes related to metastasis is also affected by oxygen homeostasis in the tumor microenvironment.

In addition, HIF signaling drives the secretion of lysyl oxidase LOX , LOX-like proteins, and exosomes, to establish a prometastatic environment within the lung and bones of patients with breast cancer.

Metabolic differences among cancer cells lead to differences in metastatic potential. Metastatic cancer cells depend on monocarboxylate transporter 1 MCT1 to deal with oxidative stress.

MCT1 plays a major role in circulating lactate, which is a prominent energy source for metastasizing cells.

In pancreatic ductal adenocarcinoma, ECM remodeling through cellular adhesion and compression affects these ratios. Secondary sites do not receive invading cancer cells passively. In fact, the host microenvironment, termed the premetastatic niche PMN , is selectively primed by the primary tumor even before the initiation of metastasis.

The transferred genes also enhance the ability of cells to invade other organs. Primary tumors release significant amounts of exosomes that transfer invasion-promoting factors, such as microRNAs miRNAs , to tumorigenic cancer cells. This, along with the effect of chemokines and growth factors, leads to the formation of a new microenvironment for cancer cells, immune cells, and other stromal constituents that is referred to as the PMN, 67 , 68 , 69 , 70 where metastatic cells may arrest, extravasate, and ultimately colonize.

In addition to their role in priming the PMN, exosomes exhibit properties that drive cancer cell organotropism. This metastatic bias towards certain organs stems from exosomal avidity for specific host cells. Exosome-mediated metastasis is not solely dependent upon tumor-released exosomes.

In fact, astrocyte-derived exosomes mediate the intercellular transfer of miRNAs that target the PTEN tumor suppressor gene to metastatic cancer cells, promoting invasion and brain metastasis. Age-related physical changes in the ECM promote or inhibit tumor cell motility, invasion, and metastasis.

Alterations in the motility of immune cells lead to changes in the immune microenvironment. Chromatin mutations have recently come to light as important mediators of cancer development. Chromatin alterations induce cells to gain full oncogenic characteristics.

Although no links to patient outcomes and survival have been established, microbes have been reported to confer vulnerability to specific cancers. Bacterial translocation selectively targets tumors that have rich vascular networks and chemotactic magnetism. Intratumoral bacteria further modulate the immune system.

Although some bacteria stimulate antitumoral immunity, others promote immunosuppression, affecting the response to immunotherapy.

The circadian clock controls a wide spectrum of processes in cellular physiology through metabolic and gene expression pathways. Circadian clock disruptions have been correlated with cancer initiation and progression.

Further alterations in transcription complexes and cellular metabolism drive cancer progression by influencing cancer cell interactions with the microenvironment. Cryptochrome circadian regulator 2, a circadian repressor, promotes MYC degradation.

Blocking CD36 inhibits metastatic ability, suggesting that a high-fat diet specifically boosts the metastatic potential of metastasis-initiating cells. The ECM is a scaffold of interconnected macromolecules forming networks that encompass cells present in tissues and organs.

One important step in invasion is the disassembly of the ECM and its constituents through enzymes such as matrix metalloproteinases MMPs. The changes in nutrient accessibility and metabolic reactions in tissues determine the likelihood of cancer cells to metastasize.

For example, metastatic breast cancer cells metabolize pyruvate, which is plentiful in the lungs, to drive collagen-based ECM remodeling in the lung metastatic niche. Versican, a hyalectan that is present in interstitial ECM, activates EGFR signaling via its EGF-like repeats, which leads to cancer cell growth and invasion.

CSPG4 interacts with integrin α2β1 upon collagen type VI binding to activate the phosphatidylinositol 3-kinase PI3K pathway in sarcoma cells. Lumican is an ECM protein that organizes fibril organization and circumferential growth. It plays a major role in corneal transparency, epithelial cell migration, and tissue repair.

In cancer, lumican attenuates the proliferation, migration, and invasion of breast cancer cells. It modifies cellular junctions and promotes MET through direct interactions with other ECM molecules or by the modulation of membrane receptors , and MMP Glypicans are proteoglycans that participate in developmental morphogenesis.

They play a dual role in fostering or suppressing tumorigenesis. Decreased glypican-3 expression leads to the progression of malignancies, whereas its loss is associated with poor overall survival. Serglycin is an intracellular proteoglycan that is expressed by hematopoietic cells.

Its expression drives cancer growth and metastasis. Hyaluronic acid HA is a glycosaminoglycan that is a principal constituent of the tumor stroma and cancer cell surfaces. It is an important EMT mediator and metastatic cancers express increased levels of HA, its CD44 receptor, and its synthase in the tumor cell microenvironment, particularly in breast, oral, prostate, and ovarian cancers.

HA-mediated EMT enhancement is driven by the expression of zinc finger E-box-binding homeobox 1 ZEB1 and its interaction with CD44, which in turn activates HA synthase 2 HAS2 expression. HAS2 has also been shown to be vital for the communication between cancer stem cells and tumor-associated macrophages TAMs.

The striking effect of HA on tumor progression is highly associated with its molecular weight and interactions with other proteins in the ECM. Altogether, the ECM is a complex and dynamic system that is composed of a wide spectrum of cells and matrikines that participate in invasion and metastasis.

Autophagy, the autophagosomal—autolysosomal process, is initiated by the advancement of various human cancers to metastasis. In vivo studies show that autophagy is involved in modulating tumor cell motility and invasion, cancer stem cell viability and differentiation, resistance to anoikis, EMT, metastatic cell dormancy, and escape from immune surveillance, with developing functions in forming the PMN and other metastatic facets.

It has always been puzzling how nerves emerge in the tumor microenvironment and what their role might be. Neural progenitors from the central nervous system that express doublecortin infiltrate prostate tumors and metastases.

The immune microenvironment around the tumor plays a major role in dictating the metastatic potential of the disseminating cells. A study analyzed tumors from more than people with colorectal cancer, comparing people whose tumors were metastatic with those who were not.

Sometimes, disseminated cancer cells survive and retain the ability to invade even after the removal of the primary tumor. Often, patients with pancreatic ductal adenocarcinoma develop liver metastases following surgical excision of the primary tumor.

Anesthetics during surgery also have an underlying mechanism in promoting metastatic dissemination. In murine models of breast cancer, sevoflurane led to significantly increased lung metastasis compared with that of propofol.

Intravasation, the dissemination of cancer cells to organs through the lumen of the vasculature, is mediated actively or passively. This causes genomic rearrangement to occur, which increases the metastatic potential.

Integrins are the key cellular adhesion receptors that are involved in nearly every step of cancer progression from primary tumor development to metastasis.

Metastatic cells use E-cadherin in metastatic sites to detach, disseminate, and seed. The circulatory journey is harsh for most intravasating cancer cells.

Interactions between CTCs and the microenvironmental components of circulation determine survival and the ability of CTCs to eventually extravasate in distant sites. Most CTCs circulate as single cells, whereas others travel in clusters Fig.

However, circulating clusters are much more likely to form metastases. Cancer cells circulate as single units or in clusters. After arresting at secondary sites or becoming stuck in capillaries, circulating tumor cells CTCs extravasate and colonize their new niches.

Some cells undergo dormancy as an adaptation mechanism to the new stressful environment. An important factor in the metastatic process is the ability of CTCs to adhere and extravasate through endothelial cells and colonize the PMN.

CTCs must adapt to the strict selective environment present in the lumen of the vasculature. The dissemination of CTCs is supported by close association with activated platelets and macrophages. A substantially increased number of metastases were found in the mice that received CTCs from CTC—neutrophil clusters.

In addition, upon the eradication of neutrophils in mice with breast tumors, the number of CTC—neutrophil clusters was markedly decreased. The journey of CTCs in the blood vessels is not easy. CTCs sense and respond to tissue mechanics and instigate brief or lasting tissue alterations, including ECM stiffening, compression and deformation, protein unfolding, proteolytic remodeling, and jamming transitions.

Permissive flow regimens in vascular regions, in addition to the location and efficiency of CTC lodging at distant sites, play large roles in the distant metastasis process. It is in such regions that single CTCs might sequentially form intravascular clusters. This generates immune-interacting intermediate molecules that promote extravasation and develop metastases from the surviving CTCs.

The migration of metastatic cells in circulation often relies on a spectrum of chemokines and complement components that direct tumor cells through the vasculature , and metabolic factors that result in an antioxidant effect.

It is now accepted that CTCs can exploit and survive in the bloodstream during tumor metastasis. The biological mechanisms by which tumor cells survive and grow within lymph nodes are not yet clear. In murine models, cancer cells acclimatize to the lymph node microenvironment by shifting their metabolism to fatty acid oxidation.

Enrichment of CTCs allowed their classification and subsequent tumor analysis. For a long time, the low sensitivity of CTC detection assays has halted CTC elimination.

In addition, the exclusion of patients with metastasis from clinical trials prevented faster progress. A photoacoustic method for direct use in patients with melanoma has been developed, allowing for the detection of very low numbers of CTCs in vivo and their subsequent destruction with laser pulses.

In addition, distinct DNA methylation profiles are present among CTC clusters from patients and murine models with breast cancer when compared with that of single CTCs.

When CTCs pass through small capillaries, they become entrapped. This either leads to microvascular rupture or forces the cell to undergo extravasation. Extravasation is a complex process that involves ligand—receptor interactions, chemokines, and circulating nontumor cells.

Many have reported that cancer cell extravasation occurs in a similar fashion to leukocyte transendothelial migration. Calcium flux, for instance, has been identified as a mechanism of crosstalk between the osteogenic niche and cancer cells, which promotes the progression of bone metastasis.

Circulating cells that extravasate at the target site are challenged with harsh conditions that make survival difficult. Exosomes have a role in educating bone marrow progenitor cells to become metastatic.

Hepatocytes control myeloid cell accumulation and fibrosis within the liver and thus increase the susceptibility of the liver to metastatic colonization. In murine models of pancreatic cancer, hepatocytes induce ILmediated STAT3 signaling and increase secretion of serum amyloid A1 and A2 SAA.

Inhibition of ILSTAT3-SAA signaling prevents the establishment of a PMN and inhibits liver metastasis. Establishing a vascular network is crucial for proper metastatic colonization.

Vascular mimicry drives the ability of some breast cancer cells to contribute to distant metastases through the overexpression of SERPINE2 and SLPI. Colonizing cancer cells are also capable of utilizing neuronal signaling pathways for growth and adaptation.

The proximity of breast cancer cells to neuronal synapses allows cancer cells to hijack N -methyl- d -aspartate receptor signaling to promote brain metastasis. Metastatic cancer cells use these junctions to transfer the second messenger cGAMP to astrocytes, activating the stimulator of interferon genes pathway and producing inflammatory cytokines such as IFNα and tumor necrosis factor.

In turn, these factors activate STAT1 and NF-κB pathways in brain metastatic cells, thereby supporting tumor growth and chemoresistance. By definition, cancer dormancy is an arrest phase in cancer progression that occurs during the primary tumor formation phase or after invasion into secondary sites.

In many cancer survivors, dormant cancer cells are present long after radical removal of the primary tumor and are thought to be responsible for late relapses.

Another potential explanation is that early dissemination spawns CTCs that respond to dormancy-inducing signals and enter dormancy in target organs. Regulation of tumor cell dormancy involves reciprocal crosstalk between the environment and mechanisms that control transcriptional programs. Increased p38 MAPK activity triggers the activation of the unfolded protein response, which upregulates activating transcription factor 6, thus promoting cell arrest and survival.

Dormancy and reactivation of cancer cells: The genetic and signaling pathways that govern cancer cell dormancy and subsequent reactivation involve intracellular signaling, extracellular signaling, and induction signals originating from the bone marrow niche.

Dormancy in metastatic cancer clusters occurs when the rate of cellular proliferation within the cluster is equal to the rate of apoptosis.

As such, the tumor cluster does not expand into micrometastasis. TGFβ induces DEC2, which inhibits cyclin-dependent kinase 4 and activates p27, forcing the cell to enter a state of quiescence. T cells and NK cells, in addition to macrophages, clear metastatic cells through cytolysis. Researchers have begun to understand the process that allows certain cancer cells to become dormant for periods of time and emerge later with recurring disease.

These cancer cells enter a state of latency and slow division by inhibiting a WNT protein-driven signaling pathway. To reduce the ability of the immune system to identify them, these dormant cancer cells downregulate the expression of immune cell-recognizable molecules.

Persistent host organ inflammation and the complementary establishment of neutrophilic extracellular traps may transform dormant cancer cells into aggressive metastases. Cancer cell plasticity facilitates the development of therapy resistance and malignant progression. Plasticity bestows upon cancer cells the ability to dynamically switch between a differentiated state, with limited tumorigenic potential, and an undifferentiated or cancer stem-like cell state, which is responsible for long-term tumor growth.

However, researchers remain hopeful that cancer cell plasticity can be exploited therapeutically. Some have forced the transdifferentiation of EMT-derived breast cancer cells into post-mitotic and functional adipocytes by using a combination therapy of MEK inhibitors and the antidiabetic drug rosiglitazone, thereby inhibiting the metastatic process.

In vivo studies have identified multiple genes that, when disrupted, modify the ability of tumor cells to establish metastases. By ablating Notch signaling, SOX18 is inhibited, which subsequently halts melanoma metastasis in murine models.

In many instances, glucocorticoids are used to treat patients with cancer-related complications. The progression of breast cancer is initiated by increasing stress hormone and glucocorticoid levels, which subsequently activates secondary site glucocorticoid receptors, enhances cancer colonization, and decreases survival rates.

Despite the displayed effectiveness of cytotoxic chemotherapy in treating invasive breast cancer, it has been shown that the treatment displays prometastatic effects. Metastasis suppressors inhibit cancer growth and proliferation at the metastatic site without affecting the primary tumor. For example, A-kinase anchor protein 8 is a splicing regulatory factor that suppresses EMT and breast cancer metastasis.

Most notably, miRNAs that suppress oncogenes and inhibit tumorigenic signaling have been recognized and explored as potential biomarkers and targets of metastasis.

Metastasis suppressor genes that have been identified in the literature: Metastasis suppressors halt metastatic proliferation at the secondary site without changing the primary cancer.

They work through oncogenic signaling pathways to suppress invasion and eventual colonization. The field of metastasis research is more than years old. However, metastasis remains the primary cause of cancer-related deaths.

Major obstacles lie in the lack of clinical trials that target metastasis and the lack of knowledge of the biological underpinnings that govern the metastatic process. Today, the diagnosis of metastatic cancer continues to be associated with a terminal label.

Although prevention of metastasis has been demonstrated preclinically, drug development has been hindered due to poor trial design and therapeutic strategies.

Advancements in immunotherapy have improved survival and patient outcomes in metastatic melanoma. Strategies that target pathways in the metastatic cascade have been studied and explored. However, at the time of metastasis diagnosis, cancer cells may have already seeded in the circulatory system or colonized a distant site.

Dormancy has also been studied as a potential target of metastatic colonization. Some have proposed therapies that help sustain the dormant state. Moreover, monoclonal antibodies have been developed to target single cancer cells at this stage. In addition to CTCs discussed earlier , the diagnostic and predictive potential of exosomes renders them key for liquid biopsies.

The brain continues to be a special site for metastasis, as colonizing cells are offered a safe haven through the existence of the blood—brain barrier BBB.

The BBB allows the crossing of tumor cells and prevents the passage of therapeutic agents. Overall, metastasis is a complex challenge that requires more than one therapeutic agent for effective inhibition. Therefore, embracing the combination therapy model and targeting multiple pathways simultaneously seems to be key to countering the significant genomic and phenotypic alterations presented by metastatic cancer cells.

Metastasis is the final frontier in cancer for which more efficacious therapies are needed. However, the development of effective treatments is contingent upon understanding the underpinnings that govern the metastatic process from start to finish.

As such, exploring metastatic evolution is necessary to be able to design better therapeutics in the future. Luzzi, K. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

Article CAS PubMed PubMed Central Google Scholar. Maitra, A. Molecular envoys pave the way for pancreatic cancer to invade the liver. Nature , — Article CAS PubMed Google Scholar.

Massague, J. Metastatic colonization by circulating tumour cells. Hanahan, D. Hallmarks of cancer: the next generation. Cell , — Steeg, P. Tumor metastasis: mechanistic insights and clinical challenges.

Lambert, A. Emerging biological principles of metastasis. Bakhoum, S. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature , Tabassum, D. Tumorigenesis: it takes a village. Cancer 15 , — Gundem, G.

The evolutionary history of lethal metastatic prostate cancer. Clark, A. Modes of cancer cell invasion and the role of the microenvironment. Cell Biol. Cheung, K. A collective route to metastasis: seeding by tumor cell clusters.

Science , — Fouad, Y. Revisiting the hallmarks of cancer. Cancer Res. CAS PubMed PubMed Central Google Scholar. Ye, X. Epithelial-mesenchymal plasticity: a central regulator of cancer progression.

Trends Cell Biol. Knott, S. Asparagine bioavailability governs metastasis in a model of breast cancer. Nieto, M. Emt: Cell , 21—45 Katsuno, Y. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression.

De Craene, B. Regulatory networks defining EMT during cancer initiation and progression. Cancer 13 , 97— Article PubMed CAS Google Scholar. Pastushenko, I. Identification of the tumour transition states occurring during EMT. Erdogan, B. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin.

Rankin, E. Hypoxic control of metastasis. Lamouille, S. Molecular mechanisms of epithelial-mesenchymal transition. Valastyan, S. Tumor metastasis: molecular insights and evolving paradigms.

Fischer, K. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Zheng, X. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Diepenbruck, M. Epithelial-mesenchymal transition EMT and metastasis: yes, no, maybe? Esposito, M. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Lawson, D. Tumour heterogeneity and metastasis at single-cell resolution.

Gene expression profiling predicts clinical outcome of breast cancer. Article Google Scholar. Ramaswamy, S. A molecular signature of metastasis in primary solid tumors. Hunter, K. Genetic background is an important determinant of metastatic potential. Robinson, D.

Integrative clinical genomics of metastatic cancer. Birkbak, N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell. Article PubMed Google Scholar. Yang, D. Intertumoral heterogeneity in SCLC is influenced by the cell type of origin. Cancer Discov. Ganesh, K. L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer.

Cancer 1 , 28—45 Article PubMed PubMed Central Google Scholar. Mlecnik, B. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. Carnero, A. The hypoxic microenvironment: a determinant of cancer stem cell evolution.

Bioessays 38 Suppl 1 , S65—S74 Ratcliffe, P. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer.

Semenza, G. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Harris, A. Hypoxia—a key regulatory factor in tumour growth. Cancer 2 , 38—47 Garcia-Heredia, J. Genetic modification of hypoxia signaling in animal models and its effect on cancer. VHL and p tumor suppressors team up to prevent cancer.

Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 32 , — Hockel, M. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix.

Brizel, D. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. CAS PubMed Google Scholar. Noman, M. Crosstalk between CTC, immune system and hypoxic tumor microenvironment.

Cancer Microenviron. Tasdogan, A. Metabolic heterogeneity confers differences in melanoma metastatic potential. Papalazarou, V. The creatine—phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis.

Peinado, H. Pre-metastatic niches: organ-specific homes for metastases. Cancer 17 , — Zomer, A. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior.

Cancer-cell transfer filmed. Weidle, U. The multiple roles of exosomes in metastasis. Cancer Genomics Proteom. Article CAS Google Scholar. Tickner, J. Functions and therapeutic roles of exosomes in cancer. Front Oncol. Harris, D. Exosomes released from breast cancer carcinomas stimulate cell movement.

PLoS ONE 10 , e Article PubMed PubMed Central CAS Google Scholar. Singh, R. Exosome-mediated transfer of miRb promotes cell invasion in breast cancer.

Cancer 13 , Higginbotham, J. Amphiregulin exosomes increase cancer cell invasion. McCready, J. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation.

BMC Cancer 10 , Fu, H. The emerging roles of exosomes in tumor-stroma interaction. Cancer Res Clin.

Interestingly, indefinite metastawis correlates with the depletion of a modular, early rigidity sensor, whereas restoring these Inhibiting cancer cell metastasis in tumor cells Inhibiting cancer cell metastasis tumor growth on caner surfaces and metastases. Canecr, normal and tumor cells from Inhibitin different tissues Inhibiting cancer cell metastasis transformed growth without Ginger energy balls recipe early rigidity sensor. When sensors are restored in tumor cells by replenishing depleted mechanosensory proteins that are often cytoskeletal, cells revert to normal rigidity-dependent growth. Surprisingly, transformed growth cells are sensitive to mechanical stretching or ultrasound which will cause apoptosis of transformed growth cells Mechanoptosis. Mechanoptosis is driven by calcium entry through mechanosensitive Piezo1 channels that activate a calcium-induced calpain response commonly found in tumor cells. Since tumor cells from many different tissues are in a transformed growth state that is, characterized by increased growth, an altered cytoskeleton and mechanoptosis, it is possible to inhibit growth of many different tumors by mechanical activity and potentially by cytoskeletal inhibitors. Thank you for visiting nature. You are using a Inhibiting cancer cell metastasis metastwsis with limited support for CSS. To obtain the best experience, we cfll you use a more up to Organic eco-tourism destinations browser metadtasis turn off Inhibiting cancer cell metastasis metastasiw in Inhibiting cancer cell metastasis Explorer. In mstastasis meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Here, we screened compounds inhibiting breast cancer cell proliferation with HPIP fused with green fluorescent protein as a reporter. A novel agent named TXX derived from rimonabant, an antagonist of cannabinoid receptor 1 with anticancer effects, has been discovered to reduce HPIP expression and has greater inhibitory effects on breast cancer cell growth and metastasis in vitro and in vivo than rimonabant. TXX regulates HPIP downstream targets, including several important kinases involved in cancer development and progression e. Inhibiting cancer cell metastasis

Author: Shakalkree

1 thoughts on “Inhibiting cancer cell metastasis

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com